Aminoglycoside-induced nephrotoxicity

Journal of Pharmacy Practice

Volumn 27, Issue 6, 2014, Pages 573-577

  Wargo, Kurt A ^a   Edwards, Jonathan D ^b  

^a AUBURN UNIVERSITY   (United States)

^b HUNTSVILLE HOSPITAL   (United States)

Author keywords

Aminoglycoside; Dosing; Nephrotoxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; GENTAMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; DRUG RESISTANCE; HUMAN; INCIDENCE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OTOTOXICITY; PROTEIN SYNTHESIS; RIBOSOME; RISK FACTOR; CHEMICALLY INDUCED; KIDNEY DISEASE;

AMIKACIN; ANTI-BACTERIAL AGENTS; GENTAMICINS; HUMANS; KIDNEY DISEASES; TOBRAMYCIN;

EID: 84910096952     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014546836     Document Type: Article

References (52)

1. Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am. 2009 ; 23 (4). 1053-1075
2. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol. 1995 ; 39 (6). 597-603
3. Antibiotic. 14 th ed. Melbourne: Therapeutic Guidelines; 2010. Melbourne: Therapeutic Guidelines ; 2010:
4. Bakker-Woudenberg IA, Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med. 1990 ; 16 (suppl 3). S229 - S234
5. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 ; 32 (3). 289-297
6. Mandell GL, Bennett JE, Dolin R Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7 th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010. Philadelphia, PA: Churchill Livingstone/Elsevier ; 2010:
7. Becker B, Cooper MA. Aminoglycoside antibiotics in the 21st century. ACS Chem Biol. 2013 ; 8 (1). 105-115
8. Paterson DL, Robson JMB, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Internal Med. 1998 ; 13 (11). 735-739
9. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 ; 74 (5). 519-528
10. Mingeot-Leclereq MP, Tukens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999 ; 43 (5). 1003-1012
11. Burton ME, Shaw LM, Schentag JJ, et al Applied Pharmacokinetics and Pharmacodynamics. 4 th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006. Philadelphia, PA: Lippincott, Williams & Wilkins ; 2006:
12. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2003 ; 17 (3). 503-28
13. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011 ; 79 (1). 33-45
14. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984 ; 100 (3). 352-357
15. Prins JM, Weverling GJ, de Blok K, et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother. 1996 ; 40 (11). 2494-2499
16. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 ; 45 (1). 22-27
17. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991 ; 27 (suppl C). 41-47
18. Hawser SP, Bouchillon SK, Hoban DJ, et al. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents. 2009 ; 34 (6). 585-588
19. Kays SE, Crowell WA, Johnson MA. Iron supplementation increases gentamicin nephrotoxicity in rats. J Nutr. 1992 ; 121 (11). 1869-1872
20. Trollfors B, Alestig K, Krantz I, et al. Quantitative nephrotoxicity of gentamicin in nontoxic doses. J Infect Dis. 1980 ; 141 (3). 306-309
21. Klastersky J, Hensgens C, Henri A, et al. Comparative clinical study of tobramycin and gentamicin. Antimicrob Agents Chemother. 1974 ; 5 (2). 133-138
22. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999 ; 43 (5). 1003-1012
23. Parsons PP, Garland HO, Harpur ES, et al. Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury. Br J Pharmacol. 1997 ; 122 (3). 570-576
24. Banday AA, Farooq N, Priyamvada S, et al. Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. Life Sci. 2008 ; 82 (9-10). 450-459
25. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy?. Clin Pharmacokinet. 1994 ; 27 (1). 32-48
26. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996 ; 312 (7027). 338-345
27. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy. 1996 ; 16 (6). 1093-1102
28. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996 ; 124 (8). 717-725
29. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996 ; 37 (4). 645-663
30. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 ; 341 (8841). 335-339
31. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999 ; 43 (7). 1549-1555
32. Prins JM, Buller HR, Kuijper EJ, et al. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections - a randomized clinical trial. J Antimicrob Chemother. 1994 ; 33 (4). 823-835
33. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999 ; 19 (11). 1252-1260
34. Freeman CD, Nicolau DP, Belliveu PP, et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997 ; 39 (6). 677-686
35. Davis BD. Mechanism of the bactericidal action of the aminoglycosides. Microbiol Rev. 1987 ; 51 (3). 341-350
36. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986 ; 108 (5 pt 2). 835-840
37. Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med. 1976 ; 61 (4). 493-497
38. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 ; 77 (4). 657-662
39. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 ; 155 (1). 93-99
40. Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects, focus on aminoglycosides. Clin Pharmacokinet. 1994 ; 27 (5). 377-392
41. Zhanel GG, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991 ; 25 (2). 153-163
42. Daikos GL, Loans VT, Jackson GG. First-exposure adaptive resistance to aminog1ycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991 ; 35 (1). 117-123
43. Verpooten GA, Giuliano RA, Verbist L, et al. Once daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 ; 45 (1). 22-27
44. Vandewalle A, Farman N, Morin JP, et al. Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney Int. 1981 ; 19 (4). 529-539
45. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infec Dis. 1997 ; 24 (5). 786-795
46. Zaske DE, Sawchuk RJ, Gerding DN, et al. Increased dosage requirements of gentamicin in bum patients. Trauma. 1976 ; 16 (10). 824-828
47. Watling SM, Dasta IF. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother. 1993 ; 27 (3). 351-357
48. Marik PE, Havlik I, Monteagudo SE, et al. The pharmacokinetics of amikacin in critically ill adult and pediatric patients: comparison of once- vs. twice-daily dosing regimens. Antimicrob Chemother. 1991 ; 27 (suppl C). 81-89
49. Gill MA, Kern JW. Altered gentamicin distribution in ascitic patients. Am Hosp Pharm. 1979 ; 36 (12). 1704-1706
50. Hessen MT, Pitsakis PG, Levison ME. Absence of a postantibiotic effect in experimental pseudomonas endocarditis treated with imipenem, with or without gentamicin. Infect Dis. 1988 ; 158 (3). 542-548
51. Potel G, Caillon , Fantin B, et al. Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation. Antimicrob Agents Chemother. 1991 ; 35 (1). 111-116
52. Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001 ; 21 (4). 443-451